OMKAR PHARMACHEM (OMKARPH) | Financial Analysis & Statements
OMKAR PHARMACHEM LTD. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Gross Profit
0
Operating Income
358.0K
Net Income
266.0K
EPS (Diluted)
₹0.03
Balance Sheet Metrics
Total Assets
96.0M
Total Liabilities
1.7M
Shareholders Equity
94.3M
Debt to Equity
0.02
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
OMKAR PHARMACHEM Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.4M | 5.4M | 5.4M | 5.4M | 2.7M |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 5.4M | 5.4M | 5.4M | 5.4M | 2.7M |
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 224.0K | 251.0K | 207.0K | 203.0K | 175.0K |
| Other Operating Expenses | 621.0K | 673.0K | 659.0K | 724.0K | 683.0K |
| Total Operating Expenses | 845.0K | 924.0K | 866.0K | 927.0K | 858.0K |
| Operating Income | 2.9M | 2.8M | 3.1M | 2.7M | 302.0K |
| Operating Margin % | 53.0% | 51.6% | 57.1% | 49.4% | 11.2% |
| Non-Operating Items | |||||
| Interest Income | 22.0K | 35.0K | 30.0K | 0 | - |
| Interest Expense | 181.0K | 292.0K | 468.0K | 563.0K | 566.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 2.7M | 2.5M | 2.6M | 2.1M | -359.0K |
| Income Tax | 691.0K | 637.0K | 667.0K | 274.0K | -2.6M |
| Effective Tax Rate % | 25.6% | 25.2% | 25.2% | 13.0% | 0.0% |
| Net Income | 2.0M | 1.9M | 2.0M | 1.8M | 2.2M |
| Net Margin % | 37.2% | 35.0% | 36.6% | 33.9% | 82.0% |
| Key Metrics | |||||
| EBITDA | 2.9M | 2.9M | 3.1M | 2.7M | 311.0K |
| EPS (Basic) | ₹0.20 | ₹0.19 | ₹0.20 | ₹0.18 | ₹0.22 |
| EPS (Diluted) | ₹0.20 | ₹0.19 | ₹0.20 | ₹0.18 | ₹0.22 |
| Basic Shares Outstanding | 10084000 | 10084000 | 10084000 | 10084000 | 10084000 |
| Diluted Shares Outstanding | 10084000 | 10084000 | 10084000 | 10084000 | 10084000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
OMKAR PHARMACHEM Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.1M | 716.0K | 1.3M | 2.1M | 439.0K |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 972.0K | 486.0K | 486.0K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 585.0K | 639.0K | - | - | - |
| Total Current Assets | 2.7M | 1.8M | 2.6M | 2.9M | 709.0K |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 183.0K | 183.0K | 159.0K | 159.0K | 91.0K |
| Goodwill | 12.0K | 16.0K | 0 | 0 | 0 |
| Intangible Assets | 12.0K | 16.0K | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | -21.0K | 37.0K | -4.0K | - |
| Total Non-Current Assets | 93.4M | 94.1M | 94.7M | 95.4M | 95.6M |
| Total Assets | 96.0M | 95.9M | 97.3M | 98.3M | 96.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | 1.2M | 3.0M | 6.2M | 9.3M | 9.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 144.0K | 345.0K | 30.0K | 248.0K | 193.0K |
| Total Current Liabilities | 1.7M | 3.6M | 6.9M | 9.8M | 9.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | - | - | -30.0K | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.7M | 3.6M | 6.9M | 9.8M | 9.7M |
| Equity | |||||
| Common Stock | 100.8M | 100.8M | 100.8M | 100.8M | 100.8M |
| Retained Earnings | -6.5M | -8.5M | -10.4M | -12.4M | -14.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 94.3M | 92.3M | 90.4M | 88.5M | 86.6M |
| Key Metrics | |||||
| Total Debt | 1.2M | 3.0M | 6.2M | 9.3M | 9.0M |
| Working Capital | 955.0K | -1.8M | -4.2M | -6.9M | -9.0M |
Balance Sheet Composition
OMKAR PHARMACHEM Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 2.7M | 2.5M | 2.6M | 2.1M | -359.0K |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -432.0K | 171.0K | -486.0K | -540.0K | -90.0K |
| Operating Cash Flow | 2.4M | 3.0M | 2.6M | 2.1M | 113.0K |
| Investing Activities | |||||
| Capital Expenditures | -40.0K | -93.0K | 0 | -68.0K | 0 |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | -40.0K | -93.0K | 0 | -68.0K | 0 |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -1.8M | -3.2M | -3.1M | 273.0K | 369.0K |
| Free Cash Flow | 2.4M | 2.9M | 2.8M | 2.0M | 224.0K |
| Net Change in Cash | 553.0K | -286.0K | -461.0K | 2.3M | 482.0K |
Cash Flow Trend
OMKAR PHARMACHEM Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
327.78
Price to Book
3.13
Price to Sales
58.34
PEG Ratio
-5.03
Profitability Ratios
Profit Margin
16.73%
Operating Margin
37.71%
Return on Equity
2.13%
Return on Assets
2.09%
Financial Health
Current Ratio
5.84
Debt to Equity
0.00
Beta
0.10
Per Share Data
EPS (TTM)
₹0.09
Book Value per Share
₹9.44
Revenue per Share
₹0.51
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| OMKARPH | 297.5M | 327.78 | 3.13 | 2.13% | 16.73% | 0.00 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.




